Kornimate/medical-research-clean huggingface dataset:
interval training versus electro acupuncture on liver functions in patients with non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: in this study, the investigators compare the effect of interval training exercise and electroacupuncture on liver functions in non-alcoholic fatty liver disease patients

fifty patients suffering from nonalcoholic fatty liver disease (nafld) will be recruited in this study with age ranged from 30-55 years old from both sexes, chosen from internal medicine department at kasr el aini hospital and from the outpatient clinic of nutrition and cardiovascular disorders at the faculty of physical therapy cairo university, they were divided in to two groups:group (1): twenty-five patients suffering from nonalcoholic fatty liver disease (nafld), and taking their standard medications in addition to electroacupuncture at points of lr3 (taichong), lr14 (qimen), gb 34(yanglingquan) and st36 (zu san li). group (2): twenty-five patients suffering from nonalcoholic fatty liver disease(nafld) and taking their standard medications in addition to aerobic interval training exercise.lab investigations of: aspartate aminotransferase (ast), alanine aminotransferase (alt), triglycerides (tg) and c-reactive protein (crp).to judge liver functions

Eligibility criteria:
inclusion criteria: 1. sixty patients suffering from nonalcoholic fatty liver disease (nafld). 2. their age will be ranged from 30-55 years old. 3. body mass index (30 - 40) 4. all patients are medically stable. exclusion criteria: * patients with hepatitis c \& b * acute and chronic significant illnesses that may interfere with actual training, severe ventricular arrhythmia, hemodynamic deterioration or exercise-induced arrhythmia at baseline testing. * co-morbidities that limit exercise tolerance (hemoglobin 10 g/dl, a chronic obstructive pulmonary disease with fev1 50%). * hypertension (resting blood pressure \>140/90 mmhg). * heart failure, inability to exercise, or drug abuse. * pacemakers * pregnancy * epileptic seizures * cancer
cognitive intervention in mild cognitive impairment with or without white matter hyperintensities

Conditions: Mild Cognitive Impairment

Summary: this is a non-pharmacological study evaluating the differential effects of a computerized cognitive stimulation program according to the existence or not of white matter hyperintensities in elderly with mild cognitive impairment.

white matter hyperintensities (wmh) are increasingly recognized as a factor determining the heterogeneity of mild cognitive impairment (mci) and have been associated to executive and processing speed impairment. cognitive interventions in mci remain quite limited for these mci with vascular profile and studies often distinguish patients by clinical subtypes rather than brain profile before an intervention. considering magnetic resonance imaging (mri) data, this study investigated the effects of a computer-based cognitive stimulation (ccs) program on mci with wmh compared to mci without wmh.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment * with and without white matter hyperintensities * mri available or accept to perform one * no engagement in other cognitive intervention program exclusion criteria: * psychiatric and neurological disorders * history of alcohol or other substance abuse * sensory and/or motor deficit affecting the use of a tablet
long or very long-limb gastric bypass in superobese

Conditions: Obesity

Summary: the goal of this study is to compare the clinical efficacy (weight loss and metabolic changes) of long (150 cm) versus very long (250cm) roux alimentary limb gastric bypass in superobese (bmi\>50) patients.

the study is a multicentre trial in which superobese (bmi\>50) patients will be randomly assigned (in a 1:1 ratio) for laparoscopic gastric roux-en-y gastric bypass with: a) long (150 cm) or b) very long (250cm) alimentary roux limb. patients will be included from three hospitals: kaunas university of medicine hospital (lithuania), klaipeda district hospital (lithuania), vaasa central hospital (finland) ) where preoperative investigation, the same technique surgical procedures and follow up will be performed acording approved protocol. approximate duration of subject participation subjects in the study will participate for approximately 5 years: * preoperative investigation and surgery 3- 5 days in the hospital; * first follow up visit: 6 months after surgery; * next follow up visits: 12, 24, 36, 48 months after surgery; * last follow up visit: 5 years after surgery. * the interim results after 12, 24 and 36 months will be calculated and presented before end of the study.

Eligibility criteria:
inclusion criteria: * hospitalized male or female subjects 18-65 years of age. * obese subjects with body mass index (bmi= kg/m²)\>50 * patients without mental or nervous disorders interfering with adequate evaluation of one's health condition. * patients who read the informed consent form and gave a written consent to participate in the study. exclusion criteria: * previous open abdominal surgery, except appendectomy, cholecystectomy and gynaecological procedures. * presence of any significance cardiac, hepatic, renal, blood, alimentary tract disease which may lead to system or organ failure in intraoperative or postoperative period. * pregnant women. * subjects taking immunosuppressive therapy. * any concomitant condition that, in the opinion of the investigator, would preclude an operation and postoperative follow up acording to a protocol

Keywords: gastric bypass obesity superobese
effects of an online meditation course on quality of life

Conditions: Quality of Life

Summary: many interventions in the field of meditation are becoming increasingly popular and have gained worldwide acceptance over the past years, both in terms of health, but also psychological aspects. on the other hand, controversial and sometimes hypercritical positions are on the rise, questioning the positive effects of meditation on health due to the limited availability of high-quality scientific data. with regard to a large number of meditation interventions, the systematic exploration of procedures that have not yet been scientifically evaluated - also in online settings - is a meaningful contribution to meditation research.


Eligibility criteria:
inclusion criteria: * age: 18 years or older * all persons registering for the online course * internet access * sufficient language skills, as well as cognitive and physical abilities, to participate in an online survey lasting approximately 30 minutes * active consent to the online consent form exclusion criteria - failure to provide informed consent to participate in the study

Keywords: meditation
diacon overnight closed-loop glucose control study

Conditions: Type 1 Diabetes

Summary: the objective of this in-clinic study is to test our closed-loop glucose control system in patients with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * age 18-65 years * type 1 diabetes duration \> 2 years * hba1c \< 8% * insulin pump user \> 1 year exclusion criteria: * use of medication affecting glucose metabolism * pregnancy or nursing

Keywords: type 1 diabetes glucose control closed-loop insulin pump glucose sensor
comparison of ferrisat vs placebo in anemia associated to inflammatory bowel disease during anti-tnf therapy

Conditions: Inflammatory Bowel Disease

Summary: anemia is the the most frequently extradigestive symptom for inflammatory bowel disease. this is due to iron deficiency and inflammation. most of treatments aim to control inflammation using anti-tnf alpha therapy which should theorically reduce anemia. the aim of the study is to show that perfusion of iron associated to anti-tnf therapy should reduce anemia and improve quality of life of patients.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * crohn's disease or ulcerative colitis defined according to the usual endoscopic, histological, and radiological criteria * under anti-tnf therapy or indication for starting an anti-tnf therapy * anemia defined according to world health organization (hemoglobin under 13g/dl for man and hemoglobin under 12g/dl for woman) * iron deficiency anemia defined as: * ferritinemia under 100 if c-reactive protein under normal value or - ferritinemia between 30 and 100 if c-reactive protein above normal value exclusion criteria: -

Keywords: inflammatory bowel disease anemia anti-tnf alpha theray ferrisat perfusion
prophylactic laser treatment of drusen maculopathy

Conditions: Age-related Macular Degeneration

Summary: to study the effect of mild laser treatment on the incidence of exudative complications in soft drusen maculopathy. we hypothesise that mild laser treatment causing a proliferation of the retinal pigment epithelium and enhancing the capacity of clearing drusen material from bruch's membrane.


Eligibility criteria:
inclusion criteria: * \> 55 years of age, * soft drusen maculopathy, * va 0.8-1.0 exclusion criteria: * va \<0.8, * pigment clumps, * ped, * cnv, * atrophy, * haemorrhage, * diabetes retinopathy, * sign cataract, * glaucoma

Keywords: age-related macula degeneration prophylactic laser treatment exudative complication
clinical efficacy of conservative treatment in female patients with plevic congestion syndrome

Conditions: Pelvic Congestion Syndrome

Summary: the article presents the results of a randomized, placebo-controlled study of the conservative treatment with daflon (detralex) in female patients with pelvic congestion syndrome .


Eligibility criteria:
inclusion criteria: •the presence of pelvic varicose veins verified by transvaginal and transabdominal duplex ultrasound scanning exclusion criteria: * severe disease of the gastrointestinal tract or hematopoietic system * terminal stage of cardiovascular, respiratory, renal or hepatic failure * grade iv malignancy * peripheral artery disease (pad) of the lower extremities, any type of diabetes, or mental disease. * pregnant women at any gestational age, women who gave birth less than 12 months ago, and breastfeeding mothers.
study of low-dose total skin electron beam therapy in mycosis fungoides

Conditions: Mycosis Fungoides

Summary: the purpise of this study was to determine the effect of low-dose (4 gy) total skin electron beam therapy as a second-line treatment of stage ib-ii mycosis fungoides.

current treatment modalities are usually not curative and having treatment options suitable for the long-term control therefore essential. electron beam therapy is generally applied to the skin in total doses of 30-36 gy over a 8-10 week period.due to the potential risk of toxicity including bone marrow supression, no more than 2-3 courses in a life time are generally recommended. in the current study we explored the possibility of using lower radiation doses for total skin electron beam therapy for long-term disease control.

Eligibility criteria:
inclusion criteria: * histologically confirmed mycosis fungoides stage i-ii with failure to obtain full remission after standard puva treatment or relapse within 4 months of puva treatment exclusion criteria: * under 18 years, pregnancy, other somatic diseases with a life expentancy under 1/2 years, psycological disorder preventing the patient to understand the information and cooperate in the treatment
feasibility, safety and acceptability of a mobile health delivered exercise training program in patients with nonalcoholic steatohepatitis

Conditions: NASH - Nonalcoholic Steatohepatitis; NASH; Exercise; Liver

Summary: this study will be a pilot study to evaluate the feasibility, safety and acceptability of exercise and liver fitness (el-fit), a mhealth exercise training program previously validated in patients with cirrhosis in patients with nonalcoholic steatohepatitis.


Eligibility criteria:
inclusion criteria: * adults age \>18 years * evidence of nash indicated by at least one of the following * liver biopsy with evidence of steatohepatitis (nas \>=4) within 6 months of the screening interval or; * historical imaging study (e.g., ultrasound, ct, mri) with hepatic steatosis and one of the following non-invasive tests within 6 months of the screening interval: i. fib-4 \>= 1.3 or; ii. nfs \>= -1.44 or; iii. elf \>= 7.7 or; iv. vcte kpa \>=8 or; v. arfi \>=1.3 or; vi. fast \>= 0.35 or; vii. mre kpa \>=2.55 or; viii. mast \> 0.165 or; * possession of a smartphone exclusion criteria: * active cardiac symptoms precluding participation in vigorous exercise * active or recent participation in exercise training program within the last 90 days * active or recent weight-loss supplement use within the last 90 days (does not include glp-1 receptor agonist use) * active illicit substance use * cancer that is active * cirrhosis * exercise identified to be unsafe by study pi or el-fit mhealth program * inability to provide informed consent * inability to walk \> 2 blocks * institutionalized/prisoner * other chronic liver disease (e.g., viral hepatitis)
preventing adolescents from entering the juvenile justice system

Conditions: Substance Use; Delinquency

Summary: this randomized controlled study tests an innovative juvenile diversion model that integrates evidence-based family therapy.immediate and longer term effects of the family intervention will be compared to services as usual with 120 adolescents participating in miami-dade's civil citation program.

this study proposes to rigorously test the innovative civil citation program (ccp)with an integrated evidence-based family intervention, multidimensional family therapy\[mdft\](liddle, 2002). the study sample includes youth referred to the ccp throughout miami-dade county and who according to ccp screening are rated as high risk for re-offending. youth are 12-17 years old with a first or second misdemeanor charge (excluding any gang, violence, or sex crimes charge). nearly all (97%) of these youth are ethnic minorities (hispanic and african american). they are at risk for school failure, substance use, and chronic delinquency due to drug availability in their communities, poor family functioning, peer drug use/delinquency, and school failure / disengagement. 120 youth who enter the civil citation program and are eligible for the study will be assigned to one of the two interventions: ccp+sau or the experimental intervention, ccp+mdft. the study asks a classical services research question(compton et al, 2005) - does the addition of a family therapy intervention, multidimensional family therapy, into an existing diversion program significantly enhance the program outcomes in key outcome domains: recidivism, substance use, delinquency, school and family functioning.

Eligibility criteria:
inclusion criteria: * youth 12 to 17 years old * parent or guardian willing to participate in assessments/treatment * demonstrate risk for mental health, substance abuse, or anger/adjustment problems on the juvenile services department screening warranting intervention but not requiring residential treatment exclusion criteria: * youth under the age of 12 or over the age of 18 * parent/guardian not willing to participate in assessments and treatment * youth not demonstrating mental health, substance abuse or anger/adjustment problems * youth requiring residential treatment * youth with severe mental illness or retardation

Keywords: adolescents family-based treatment multidimensional family therapy
narcotic vs. non-narcotic pain regimens after pediatric appendectomy

Conditions: Appendicitis; Pain, Postoperative

Summary: there is concern that pain prescription after outpatient pediatric surgical procedures is excessive and is in excess of patient need. current practice following pediatric appendectomy is to prescribe all children with 5-15 doses of narcotic pain medication upon discharge regardless of their age, severity of appendicitis, or pain control in the hospital. this study examines the amount of narcotic pain control required by pediatric patients after undergoing appendectomy using a randomized controlled trial study design. pain control will be assessed with a post-operative pain scale, patient satisfaction survey, and parent satisfaction survey on the days following surgery and at post-operative follow-up. the hypothesis is that the pain scores and patient satisfaction surveys will show no difference in post-operative pain control between the two arms.

there is concern that pain prescription after outpatient pediatric surgical procedures is excessive and is in excess of patient need. current practice following pediatric appendectomy is to prescribe all children with 5-15 doses of narcotic pain medication upon discharge regardless of their age, severity of appendicitis, or pain control in the hospital. this study examines the amount of narcotic pain control required by pediatric patients after undergoing appendectomy using a randomized controlled trial study design. children admitted after undergoing surgical management for a diagnosis of acute appendicitis will be randomized at discharge to a narcotic arm or a tylenol/motrin arm. the narcotic arm will receive the standard of care narcotic prescription. the tylenol/motrin arm will receive education to use tylenol and motrin for pain control as well as a paper prescription provided for the sole purpose of rescue. pain control will be assessed with a post-operative pain scale, patient satisfaction survey, and parent satisfaction survey on the days following surgery and at post-operative follow-up. the hypothesis is that the pain scores and patient satisfaction surveys will show no difference in post-operative pain control between the two arms.

Eligibility criteria:
inclusion criteria: * children ages 0 to 18 years old * patients have undergone appendectomy by any technique (open, laparoscopic, single-port) exclusion criteria: * patients on chronic opioids * patient undergoes a more extensive or additional procedures at the time of operation due to complications or other indication * pregnancy

Keywords: appendicitis postoperative pain patient satisfaction children pediatric narcotic pain control
the safety and efficacy of q-1802 combined with xelox in gastrointestinal tumors

Conditions: Gastroesophageal Junction (GEJ) Adenocarcinoma

Summary: the main purpose of this study is to evaluate safety, tolerability and the efficacy of q-1802 plus soc compared with soc. .pharmacokinetics (pk) ,pharmacodynamics (pd) of q-1802 and the immunogenicity profile of q-1802 will be evaluated as well.

this study is a multicenter, open label, phase ⅰb/ⅱ clinical study conducted in unresectable patients with advanced or recurrent metastatic claudin18.2 positive (medium and high expression) and her-2 negative primary gastric adenocarcinoma or gastric esophageal junction adenocarcinoma. the phase ib dose escalation study included two dose groups each combined with the xelox standard treatment regimen. perform dose escalation to obtain mtd and/or rp2d doses for combined administration. the phase ii study adopted an open label parallel randomized controlled design. further observe the efficacy and safety of q-1802 combined with xelox regimen in treating patients with moderate to high expression of claudin 18.2, and compare and analyze the efficacy and safety of q-1802 combined with xelox regimen and xelox regimen alone.

Eligibility criteria:
inclusion criteria： patients with at least one measurable lesion per recist (v1.1); patients with medium or high expression of claudin18.2 in tumor tissue samples tested by immunohistochemistry in central laboratory were included; patients with untreated, unresectable advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with negative her-2 immunohistochemistry or fish test (her-2 immunohistochemistry 0/1+ confirmed by a qualified local or central laboratory, or 2+ confirmed negative by fish test) were included; eastern cooperative oncology group (ecog) performance status score 0 or 1 at screening and no deterioration occurs within two weeks before enrollment; life expectancy period ≥ 12 weeks; patients who have sufficient baseline organ function. exclusion criteria: receive anti-tumor treatment within 4 weeks before the first administration or within 5 half-lives of the treatment drug, whichever is shorter; patients who have previously used claudin 18.2 products for treatment; with uncontrolled diseases; who are allergic to the study drug or any of its components; patients with a history of other primary malignant tumors at the time of screening, except for cured skin basal-cell carcinoma or cutaneous squamous-cell carcinoma or cervical carcinoma in situ.

Keywords: neoplasms
analysis of intestinal defensin expression in acute gvhd

Conditions: GVHD,Acute; Ulcerative Colitis; Morbus Crohn

Summary: this study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute gvhd. the expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.

acute graft-versus-host disease (gvhd) is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-hct). acute gvhd is characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal dysbiosis, which contribute to disease pathogenesis. defensins are endogenous epithelial cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape the intestinal microbiota composition and contribute to host immunoregulation. deregulated expression of defensins has been reported in patients with colitis, including chron's disease and ulcerative colitis. in this study, the investigators aim to analyze the expression of defensins in the intestine of patients with acute gvhd to study whether it is deregulated. the results will be valuable to study the role of defensins during acute gvhd pathogenesis or as potential biomarkers for disease activity.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnostic endoscopy was performed * diagnosis results available * written informed consent * ability to understand the nature of the study and the study related procedures and to comply with them exclusion criteria: * age \< 18 years * gastrointestinal cancer * lack of informed consent